Recordati SpA (Recordati) develops, manufactures, and commercializes drugs for primary care and orphan drugs for the treatment of rare diseases. It provides a range of pharmaceuticals, proprietary and under license, for various disease conditions including a specialized segment committed to treating rare diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D activities focus on developing new specialties originating either internally or acquired through development agreements with other pharmaceutical companies and research institutes. Recordati is engaged in research and development of new drugs, with a particular focus on rare diseases. Recordati has its own facilities for the production of pharmaceutical and chemical products. The company is committed to the early-stage design of clinical trials and research and development, focusing on involving patient associations and patient feedback. Recordati collaborates with universities worldwide to develop new therapeutic uses for current treatments and promote research and development in areas such as metabolic diseases, endocrinology, and oncology. In FY2024, progress was made on clinical development and Life Cycle Management programs of key assets, including a Phase 2 study for a potential new indication for pasireotide in PBH, potential label extension in the US for osilodrostat into Cushing’s Syndrome, and discussions with the FDA on potential BLA for dinutuximab beta in neuroblastoma. Recordati also finalized work on the phase 2 program for REC 0559 in neurotrophic keratitis, which did not meet its primary endpoint. Additionally, multiple registration and regulatory activities were carried out to maintain and obtain marketing approvals for Recordati products in new territories. In November 2024, Recordati signed an agreement to acquire from Sanofi the global rights to Enjaymo, a groundbreaking biologic and the only approved targeted treatment for Cold Agglutinin Disease. In FY2024, the company spent EUR286 million on its R&D activities, which as a percentage of revenue stood at 12.2%, and grew 11.8% YoY.